Visiongain has published a new report on CNS Therapeutics Market Report 2021-2031: Forecasts by Diseases (Neurovascular Disease, Trauma, Mental Health, Degenerative, Others), by End Users (Hospitals, Home Care, Others) AND Leading National Market Analysis PLUS Analysis of Leading CNS Therapeutics Companies AND COVID-19 Recovery Scenarios.

According to Visiongain analysis, global CNS therapeutics market is estimated to be valued at US$ xx billion in 2020. The global market is expected to witness a CAGR of xx% from 2021 to 2026 and is expected to reach US$ xx billion in 2026 from its previous value of US$ xx billion in 2021. Visiongain further anticipates that the global CNS therapeutics market will reach US$ xx billion in 2031 while growing at a CAGR of xx% from 2021 to 2031.

COVID-19 Impact on CNS Therapeutics Market
COVID-19 pandemic has wreaked havoc on the global economy and disrupted the flow of trade since the coronavirus spread in late 2019. As lockdowns were imposed in all the countries, diagnosis rates went down in majority of countries during the year hitting the drug sales for some period. Although lockdown measures have been eased up in most countries by mid-year 2020, this trend is expected to continue beyond 2020, stock up of medicines by patients is likely to propel the drug sales in majority of the developed economies, which account for majority of CNS therapeutics.

Increasing Geriatric Population to Trigger Market Growth
Geriatric population is prone to various neurological problems Alzheimer, Parkinson’s, ALS, and many more as well as chronic diseases. With such high risks of mental diseases associated with high age, increase in elderly population is currently one of the largest markets for CNS disorder treatment and is expected to be so in near future. It is estimated that, by the end of 2030, 71 million Americans which account for 20% of the overall population are expected to cross the age of 65. Such projections are expected to make the U.S. potential market for CNS drugs and therapies in near future.

With increase in age, degradation of brain cells is observed. Such factors are expected to increase the rate of degenerative disease incidence across the globe fuelling the market over the study period. There are millions of Americans with Alzheimer's disease or other type of dementias. The number of Americans with Alzheimer's or other disease will rise as the proportion of the U.S. population aged 65 and older continues to increase. Similar trend is likely to be observed in countries such as Japan, China, India and many more.

Competitive Landscape
Currently, key players are forming various strategies such as partnerships, collaborations, and continuous research and development to strengthen their position in the global CNS therapeutics market. Companies are also expanding their pipelines, distribution, and management facilities to expand their business and to hold a competitive edge in the CNS therapeutics market. The global CNS therapeutics market is consolidated in nature on account of top 10 companies accounting for over 70% of the global market share. Less number of approvals coupled with high R&D costs associated compared to other therapeutic areas is the major reason for market consolidation.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.